{"product_id":"moffitt-cancer-center-cell-coast-conference-2025","title":"Moffitt Cancer Center Cell Coast Conference 2025","description":"\u003cul\u003e\n  \u003cli\u003eTarget Audience: hematologists, oncologists, and cellular therapy practitioners\u003c\/li\u003e\n  \u003cli\u003eSample video: contact me for sample video\u003c\/li\u003e\n  \u003cli\u003eInformation:\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e1. Overview\u003c\/p\u003e\n\u003cp\u003eThe Moffitt Cancer Center Cell Coast Conference 2025 is a premier event dedicated to the latest breakthroughs in cellular cancer therapies. This course brings together leading experts to explore emerging targets, advanced engineering strategies, and next-generation modalities like CAR-T, bispecific antibodies, and TIL therapies, aiming to enhance treatment efficacy and patient care.\u003c\/p\u003e\n\u003cp\u003eJoin us for the 2nd Annual Cell Coast Conference, where leading experts, researchers, and industry pioneers will converge to explore the latest breakthroughs in cellular cancer therapy. This premier event will feature cutting-edge discussions on emerging targets, advanced engineering strategies, and next-generation therapeutic modalities, all aimed at enhancing the efficacy and delivery of cellular therapies.\u003c\/p\u003e\n\u003ch3\u003eAttendees will engage with top-tier experts and industry leaders through four dynamic session tracks:\u003c\/h3\u003e\n\u003cp\u003eNovel Targets and Approaches\u003c\/p\u003e\n\u003cp\u003eAdvanced Engineering and Modalities\u003c\/p\u003e\n\u003cp\u003eOptimizing Delivery and Efficacy\u003c\/p\u003e\n\u003cp\u003eInteractive Debates and Controversies\u003c\/p\u003e\n\u003cp\u003eThe 2nd Annual Cell Coast Conference provides an unparalleled opportunity to gain insights from world-renowned experts, participate in collaborative discussions, and network with peers driving innovation in the field. Whether you’re a researcher, clinician, or industry professional, this conference will equip you with the latest knowledge and strategies to accelerate the development of next-generation cellular therapies for cancer. Don’t miss this opportunity to be at the forefront of transformative cancer treatment advancements!\u003c\/p\u003e\n\u003cp\u003e2. Learning Objectives\u003c\/p\u003e\n\u003cp\u003eEvaluate the efficacy and toxicity management of bispecific antibody therapies for Non-Hodgkin Lymphoma and Multiple Myeloma.\u003c\/p\u003e\n\u003cp\u003eAnalyze updates in CAR-T cell therapies for ALL, solid tumors, and autoimmune diseases, including in-vivo and armored CAR-T strategies.\u003c\/p\u003e\n\u003cp\u003eDiscuss the operationalization of new therapies like Tarlatamab and the logistics of clinical care for cell therapy patients.\u003c\/p\u003e\n\u003cp\u003eCompare CAR-T versus BiTEs for hematologic malignancies and assess biomarkers for toxicity and response.\u003c\/p\u003e\n\u003cp\u003e3. Target Audience\u003c\/p\u003e\n\u003cp\u003eBest for hematologists, oncologists, and cellular therapy practitioners who want updates on CAR-T, bispecific antibodies, and TIL therapies.\u003c\/p\u003e\n\u003cp\u003eThis conference is specifically crafted for professionals in the field, including cellular therapy practitioners, hematologists, community oncologists, pharmacists, advanced practice professionals, and dedicated oncology nurses.  Particular attention will be paid to the interface between referring providers and cellular therapists, including when and how to refer patients.\u003c\/p\u003e\n\u003cp\u003e4. Topics\u003c\/p\u003e\n\u003cp\u003eBispecific Antibody Therapy in Non-Hodgkin Lymphoma and Toxicity Management\u003c\/p\u003e\n\u003cp\u003eOperationalization of Tarlatamab Therapy at Moffitt Cancer Center\u003c\/p\u003e\n\u003cp\u003eBispecific Antibody Therapy for Relapsed Refractory Multiple Myeloma\u003c\/p\u003e\n\u003cp\u003eKeynote Speaker Combination CAR T and anti-IFNG Strategies for the Management of Advanced Cancers\u003c\/p\u003e\n\u003cp\u003eNovel Cellular Therapies for Sarcoma\u003c\/p\u003e\n\u003cp\u003eCAR-T Cell Updates in ALL\u003c\/p\u003e\n\u003cp\u003eGPC3 CAR T Cells for the Management of Advanced Cancers\u003c\/p\u003e\n\u003cp\u003eCAR-T for Autoimmune Diseases\u003c\/p\u003e\n\u003cp\u003eBiomarkers for Toxicity and Response in CAR-T for Multiple Myeloma\u003c\/p\u003e\n\u003cp\u003eIn-Vivo CAR-T\u003c\/p\u003e\n\u003cp\u003eClaudin 18.2 for Gastrointestinal Malignancies\u003c\/p\u003e\n\u003cp\u003eT Cell Fitness What’s Next after BCMA CAR\u003c\/p\u003e\n\u003cp\u003eArmored CAR-T Strategies for Advanced Cancers\u003c\/p\u003e\n\u003cp\u003eAllogeneic “off the shelf” IO approaches for MDS AML\u003c\/p\u003e\n\u003cp\u003eCAR-NK Strategies for the Management of Advanced Cancers\u003c\/p\u003e\n\u003cp\u003eBladder Til Trial\u003c\/p\u003e\n\u003cp\u003eFuture of TIL Therapy\u003c\/p\u003e\n\u003cp\u003eNovel TIL Therapies in Lung Cancer\u003c\/p\u003e\n\u003cp\u003eCAR-T for Glioblastoma\u003c\/p\u003e\n\u003cp\u003eGCC19 CAR T Trial\u003c\/p\u003e\n\u003cp\u003ePractical Logistics of Clinical Care for Cell Therapy Patients\u003c\/p\u003e\n\u003cp\u003eCAR-T vs BiTEs for Hematologic Malignancies (Part 1)\u003c\/p\u003e\n\u003cp\u003eCAR-T vs BiTEs for Hematologic Malignancies (Part 2)\u003c\/p\u003e","brand":"Medicalcoursespro","offers":[{"title":"Default Title","offer_id":46405805441220,"sku":null,"price":39.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0751\/7644\/4100\/files\/Moffitt-Cancer-Center-Cell-Coast-Conference-2025.jpg?v=1784216464","url":"https:\/\/medicalcoursespro.com\/products\/moffitt-cancer-center-cell-coast-conference-2025","provider":"Medicalcoursespro","version":"1.0","type":"link"}